文献速递胸部

螺旋断层放疗立体定向体部放疗治疗原发性和转移性肺部病灶的肺功能研究

Pulmonary function in stereotactic body radiotherapy with helical tomotherapy for primary and metastatic lung lesions.
PubMed 文献 · Radiol Med · 2020-05-15

本回顾性研究报告了螺旋断层放疗(HT)实施立体定向体部放疗(SBRT)治疗肺部病灶后的结局,并推动剂量递增方案。41个原发性病灶和15个转移性病灶纳入分析,30例接受40 Gy/5次(BED 72 Gy10Gy),26例接受50 Gy/5次(BED 100Gy10Gy)。主要终点为肺毒性,次要终点为呼吸功能、局部控制和局部无进展生存。

要点

  • 急性毒性发生于18/56例患者,晚期毒性发生于8/54例。
  • FEV-1中位变化较基线:6个月为-0.5%(范围-16%至+43%),24个月为-4.00%(范围-42%至+18%)。
  • DLCO中位变化较基线:6个月为-1%(范围-38%至+36%),24个月为-12.2%(范围-48%至+11%)。

诊断标准与关键数值

  • 主要终点为肺毒性,次要终点为呼吸功能、局部控制和局部无进展生存。
  • 6个月时FEV-1变化与KPS呈显著正相关(p=0.047)。
  • 24个月时FEV-1变化与同侧肺V5呈显著负相关(p=0.006)。
  • 基线DLCO低与6个月时DLCO加重更明显相关(p=0.012)。
  • 24个月时DLCO加重与对侧肺中位剂量显著相关(p=0.003)。

临床应用与阅片要点

  • 作者报告HT实施的SBRT耐受性良好并提供良好局部控制。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIMS: This retrospective study reports outcomes after stereotactic body radiation therapy (SBRT) as delivered by helical tomotherapy (HT) for lung lesions. It promotes a dose escalation program.

METHODS: Histological and/or radiological findings and/or case histories identified 41 primary and 15 metastatic lesions. Thirty patients received 40 Gy in 5 fractions (BED 72 Gy10Gy) and 26 50 Gy in 5 fractions (BED 100Gy10Gy). Primary end point was lung toxicity. Secondary end points were respiratory function, local control and local progression-free survival.

RESULTS: Acute toxicity developed in 18/56 patients and late toxicity in 8/54. Median FEV-1 variations versus baseline were - 0.5% (range - 16 to + 43%) at 6 months and - 4.00% (range - 42 to + 18%) at 24 months. Median DLCO variations versus baseline were - 1% (range - 38 to + 36%) at 6 months and - 12.2% (range - 48 to + 11%) at 24 months. At 6 months, a significant positive correlation emerged between FEV-1 change and KPS (p = 0.047). At 24 months, a significant negative correlation emerged between FEV-1 change and the ipsilateral lung V5 (p = 0.006). A low baseline DLCO correlated with more marked DLCO worsening at 6 months (p = 0.012). At 24 months, DLCO worsening correlated significantly with the median contralateral lung dose (p = 0.003). At the last checkup, 23 patients were in complete remission, 16 were in partial remission, 5 had stable disease, and 7 were in relapse. Median follow-up was 12 months (range 5-56).

CONCLUSIONS: In patients with lung disease, SBRT, as delivered by HT, was well tolerated and provided good local control.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Falcinelli L, Mendichi M, Chierchini S, et al. Pulmonary function in stereotactic body radiotherapy with helical tomotherapy for primary and metastatic lung lesions. Radiol Med. 2020. PMID: 32415475. doi:10.1007/s11547-020-01223-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。